Treatment of AIDS-related Kaposi's sarcoma

D. W. Northfelt; J. O. Kahn; P. A. Volberding

doi:10.1016/s0889-8588(18)30442-8

Treatment of AIDS-related Kaposi's sarcoma

D. W. Northfelt, J. O. Kahn, P. A. Volberding

Research output: Contribution to journal › Review article

22 Scopus citations

Abstract

Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Epidemiologic and molecular studies of AIDS-related KS (AIDS-KS) are being performed to provide a better understanding of the etiology of the disease, so that rational therapy can be devised. Effective palliative treatment is currently available using conventional chemotherapy, radiation therapy, biologic response modifiers, and various local treatment modalities. AIDS-KS is a heterogeneous disease, and therapy must therefore be individualized, with consideration given to the patient's clinical and immunologic status.

Original language	English (US)
Pages (from-to)	297-310
Number of pages	14
Journal	Hematology/Oncology Clinics of North America
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/s0889-8588(18)30442-8
State	Published - Jan 1 1991
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/s0889-8588(18)30442-8

Fingerprint Dive into the research topics of 'Treatment of AIDS-related Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this

Northfelt, D. W., Kahn, J. O., & Volberding, P. A. (1991). Treatment of AIDS-related Kaposi's sarcoma. Hematology/Oncology Clinics of North America, 5(2), 297-310. https://doi.org/10.1016/s0889-8588(18)30442-8

@article{4b4599d3fc2e45ec996e5195aad75920,

title = "Treatment of AIDS-related Kaposi's sarcoma",

abstract = "Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Epidemiologic and molecular studies of AIDS-related KS (AIDS-KS) are being performed to provide a better understanding of the etiology of the disease, so that rational therapy can be devised. Effective palliative treatment is currently available using conventional chemotherapy, radiation therapy, biologic response modifiers, and various local treatment modalities. AIDS-KS is a heterogeneous disease, and therapy must therefore be individualized, with consideration given to the patient's clinical and immunologic status.",

author = "Northfelt, {D. W.} and Kahn, {J. O.} and Volberding, {P. A.}",

year = "1991",

month = jan,

day = "1",

doi = "10.1016/s0889-8588(18)30442-8",

language = "English (US)",

volume = "5",

pages = "297--310",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treatment of AIDS-related Kaposi's sarcoma

AU - Northfelt, D. W.

AU - Kahn, J. O.

AU - Volberding, P. A.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Epidemiologic and molecular studies of AIDS-related KS (AIDS-KS) are being performed to provide a better understanding of the etiology of the disease, so that rational therapy can be devised. Effective palliative treatment is currently available using conventional chemotherapy, radiation therapy, biologic response modifiers, and various local treatment modalities. AIDS-KS is a heterogeneous disease, and therapy must therefore be individualized, with consideration given to the patient's clinical and immunologic status.

AB - Kaposi's sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Epidemiologic and molecular studies of AIDS-related KS (AIDS-KS) are being performed to provide a better understanding of the etiology of the disease, so that rational therapy can be devised. Effective palliative treatment is currently available using conventional chemotherapy, radiation therapy, biologic response modifiers, and various local treatment modalities. AIDS-KS is a heterogeneous disease, and therapy must therefore be individualized, with consideration given to the patient's clinical and immunologic status.

UR - http://www.scopus.com/inward/record.url?scp=0026064014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026064014&partnerID=8YFLogxK

U2 - 10.1016/s0889-8588(18)30442-8

DO - 10.1016/s0889-8588(18)30442-8

M3 - Review article

C2 - 2022595

AN - SCOPUS:0026064014

VL - 5

SP - 297

EP - 310

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -